Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Home Diabetes Complications Continuous blood glucose monitoring can predict microvascular complications in type 1 diabetes

Continuous blood glucose monitoring can predict microvascular complications in type 1 diabetes

by News Source
0 comments Donate

Health Day News — A 14-day continuous glucose monitoring (CGM) trace added to the Diabetes Control and Complications Trial (DCCT) data showed that glycated hemoglobin, as well as microvascular diabetic complications, were detected in a study published online on January 8. It is said that the disease can be predicted. Diabetes technology and treatment.

Boris P. Kovatchev, Ph.D., of the University of Virginia, Charlottesville, and colleagues investigated the association of CGM indicators with microvascular complications of type 1 diabetes observed during DCCT and established time-to-arrival (TIR) ​​as a marker. For blood sugar control. Virtual CGM traces were added to each participant's original DCCT data using a multi-step machine learning procedure.

The researchers found that TIR (70 to 180 mg/dL), calculated from 14 days of virtual CGM data before each glycated hemoglobin measurement, was associated with the observed differences in glycemic control between the intensive and conventional DCCT groups. , and found TIR >60 percent and <40 percent. percentage of each of these groups. TIR, like glycated hemoglobin, was associated with the risk of development or progression of retinopathy, nephropathy, and neuropathy. TIR predicted retinopathy and microalbuminuria similarly to the original glycated hemoglobin data.

“We demonstrated a strong association between TIR and the risk of development or progression of retinopathy and the development of microalbuminuria,” the authors wrote.

Several authors disclosed relationships with the biopharmaceutical industry.

Summary/Full text

You may also like

Today’s Diabetes News, your ultimate destination for up-to-date and insightful information on diabetes, health tips, and living a fulfilling life with diabetes. Our mission is to empower and support individuals with diabetes, their loved ones, and the wider community by providing reliable, relevant, and engaging content that fosters a healthier and happier life.

Most Viewed Articles

Latest Articles

Copyright MatchingDonors.com©️ 2025 All rights reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
-
00:00
00:00
    -
    00:00
    00:00